StockNow
Log in
U.S. Markets

Merck (MRK) announces initial access plans for Alimatravir, an investigational once-monthly oral HIV pre-exposure Prophylaxis in Phase 3 development

StockNow breaking-news AI analysis

Merck announced access plans for Alimatravir, a monthly oral HIV PrEP candidate in Phase 3. This move highlights Merck's strategy to provide diversified, long-acting HIV prevention options globally.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYGeopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

Geopolitics

The draft agreed to by Iranian and Omani negotiators awaits final approval from Iran’s supreme leader, two regional officials told The Associated Press on Wednesday